L002

• UNSPSC Description:

  L002 is a potent, cell permeable, reversible and specific acetyltransferase p300 (KAT3B) inhibitor with an?IC50?of 1.98 μM[1]. L002 binds the acetyl-CoA pocket and competitively inhibits the FATp300 catalytic domain, blocks histone acetylation and p53 acetylation, and inhibits STAT3 activation[2]. L002 has the potential for hypertension‐induced cardiac hypertrophy and fibrogenesis treatment[3].

• Target Antigen:

  Histone Acetyltransferase; STAT

• Type:

  Reference compound

• Related Pathways:

  Epigenetics;JAK/STAT Signaling;Stem Cell/Wnt

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Cancer; Inflammation/Immunology; Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/l002.html

• Purity:

  99.44

• Solubility:

  DMSO : 62.5 mg/mL (ultrasonic)

• Smiles:

  O=C1C(C)=C/C(C=C1C)=N\OS(=O)(C2=CC=C(OC)C=C2)=O

• Molecular Weight:

  321.35

• References & Citations:

  [1]Rai R, et al. A novel acetyltransferase p300 inhibitor ameliorates hypertension-associated cardio-renal fibrosis. Epigenetics. 2017;12(11):1004-1013.|[2]Sun XJ, et al. The Role of Histone Acetyltransferases in Normal and Malignant Hematopoiesis. Front Oncol. 2015 May 26;5:108.|[3]Rai R, et al. Acetyltransferase p300 inhibitor reverses hypertension-induced cardiac fibrosis.J Cell Mol Med. 2019 Apr;23(4):3026-3031.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  321695-57-2